Atopic dermatitis (AD)
Conditions
Interventions
None listed
Sponsors
Pfizer Japan Inc.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Participants are eligible to be included in the study only if all of the following criteria apply: 1. Male or female participants 18 years of age or more at the time of Informed Consent is signed (Screen 1). 2. Patients have been or who are diagnosed with AD by a dermatologist. 3. Patients who gave written informed consent prior to participating in this study.
Exclusion criteria
Exclusion criteria: Participants are excluded from the study if any of the following criteria apply: 1. Patients concomitant with skin diseases which affect the area where AD skin image is photographed. 2. Patients whose symptoms are clearly in remission in the area affected by AD and whose EASI score is clearly zero. 3. Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Diagnostic accuracy of AI software for signs of severity >=2 according to EASI scores (area under the curve [AUC] of Receiver Operatorating Characteristic [ROC] curve of predictive confidence score, specificity, sensitivity, false positive rate, false negative rate, positive predictive value, and negative predictive value) | — |
Secondary
| Measure | Time frame |
|---|---|
| - Diagnostic accuracy of AI software for signs of severity 3 according to EASI scores (AUC of ROC curve of predictive confidence score, specificity, sensitivity, false positive rate, false negative rate, positive predictive value, and negative predictive value) - Diagnostic accuracy of AI software for signs of severity >=1 according to EASI scores (AUC of ROC curve of predictive confidence score, specificity, sensitivity, false positive rate, false negative rate, positive predictive value, and negative predictive value) | — |
Countries
Japan
Contacts
Public ContactKenichi Yamanaka
Pfizer Japan Inc. Medical Affairs, Inflammatory & Immunology
Outcome results
None listed